
Share
UnitedHealth and CVS posted strong profit rebounds while Centene and Elevance flagged a Medicaid turnaround ahead. But a wave of lawsuits over CMS star ratings threatens billions in bonus payments across the sector.
UnitedHealth Group remained the industry's profit leader in the third quarter, posting $4.1 billion in earnings, nearly double the $2.3 billion it reported a year earlier. Through nine months, profits reached $15.9 billion, up from $12 billion over the same period in 2025. The numbers mark continued progress in a turnaround effort that began in mid-2025, when the company stumbled badly out of the gate.
That stumble was centered largely on Optum Health. During the latest earnings call, Optum CEO Patrick Conway attributed recent gains to a "continued return to value-based care principles" at the unit's core. Revenue told a more modest story: $112.7 billion for the quarter, down slightly from $113.2 billion a year ago. The profit growth, in other words, came from execution rather than top-line expansion.
CVS Health delivered the sharpest reversal in the group. The company earned $2.2 billion in the quarter, a dramatic swing from the nearly $4 billion loss it posted in the third quarter of 2025. Revenue climbed to $108.4 billion from $102.9 billion. Yet the earnings weren't the headline. CVS stunned the market by announcing plans to split into two companies, separating CVS Pharmacy from Aetna and Caremark, which will remain bundled under the CVS Health name. The breakup is expected to close in the first half of 2028. CEO David Joyner called it "a structure and plan that are built to win and represent the best path to create value over the long term."
Cigna and Elevance Health posted identical profits of $1.4 billion for the quarter, though Cigna edged out on revenue with $73.7 billion versus Elevance's $51.4 billion. Cigna's figures represent a decline from $1.9 billion in profit and $69.7 billion in revenue a year earlier. The company's quarter was shaped by the rollout of its "Lead to One" strategy, a transformation plan built around personalized member experiences that draws on all of Cigna's business segments.
Elevance's profit ticked up slightly from $1.2 billion in the prior-year quarter, with revenue rising from $50.7 million. Executives there offered one of the more closely watched updates of the season: a cautious but real signal on Medicaid.
Medical cost trend has been the industry's persistent headache, but several payers used their Q3 calls to point toward relief on the Medicaid side. Elevance executives described 2026 as a "trough year" for its Medicaid book, with improvement likely in 2027. That expectation rests on state rate-setting processes that increasingly reflect the true cost of care and the rising acuity of Medicaid enrollees, a dynamic executives expect to intensify as states roll out work requirements starting this year.
Centene struck a similar tone. CEO Sarah London pointed to "long-term growth" potential in Medicaid, citing the same rate-setting trends Elevance flagged. London also noted progress on long-standing problem areas, including behavioral health. The company's quarterly results reflected a business still working through turbulence but moving in the right direction: a $71 million loss, a sharp improvement from the $6.6 billion loss posted a year earlier, which had been driven by a one-time impairment charge exceeding $6 billion. Revenue rose modestly to $50.6 billion from $49.7 billion.

Humana, meanwhile, offered an early read on the Medicare Advantage enrollment season that suggests the insurer is positioned for membership growth heading into 2027. CEO Jim Rechtin said early sign-up data points to gains, bolstered by momentum in new enrollments and success recapturing members lost to prior market exits. Humana's profit slipped to $162 million from $195 million a year earlier, but revenue jumped to $41.15 billion from $32.6 billion, a sign of scale even as margins stayed thin.
Beneath these earnings numbers sits a less visible but financially significant battle: a growing wave of litigation over CMS's Medicare Advantage star ratings for 2027. Centene, Aetna and Elevance have all sued the federal government in recent weeks, each arguing that CMS used unlawfully adopted measures to calculate scores that determine quality bonus payments.
The cases build on a summer ruling in Clover Health's favor, where a Georgia federal court set aside 20 measures used in 2026 scoring, a decision CMS has appealed. That ruling triggered a broader recalculation of 2026 scores and opened the door for a string of follow-on suits targeting 2027 methodology.
The dollar figures at stake are not trivial. Elevance says excluding 11 contested measures would lift scores across 12 Medicare Advantage contracts and generate $516 million in additional quality bonus payments. Aetna estimates its exposure at roughly $2 billion in 2028 bonus payments and rebate retention, with the share of its MA members in four-star-or-higher plans falling to 69% from 81% under the 2027 methodology. Centene's complaint cites a drop to 9% of members in four-star-plus plans, down from 18% the prior year, costing the company hundreds of millions in potential revenue. Each insurer argues the lower ratings carry reputational costs too, muddying the comparison tool prospective enrollees rely on to choose plans.
The Q3 numbers suggest the sector's worst Medicaid pressures may be peaking rather than worsening, a meaningful shift after several quarters of deteriorating cost trends. Elevance and Centene both frame 2026 as a bottom, not a cliff edge, with rate adjustments expected to catch up to acuity in 2027. That's a constructive signal for investors who have been pricing in continued Medicaid margin compression.
The star ratings litigation is the wildcard to watch into 2027. With CMS's appeal of the Clover ruling still pending and at least three major insurers now challenging their 2027 scores, the outcome could reshape quality bonus payments across the industry, not just for the plaintiffs. Investors should track the Georgia Southern District docket closely. A ruling that extends the Clover precedent broadly would represent a real tailwind for MA-heavy insurers heading into 2028 guidance season. A loss, by contrast, would lock in lower bonus payments and give ammunition to insurers already wary of MA's shrinking margins.
Tags
Original Sources
Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results
↗ https://www.fiercehealthcare.com/payers/positive-medicaid-signals-open-enrollment-trends-recapping-major-payers-q3-results
About the author
Marcus began tracking AI's market implications in 2016, noticing AI-related patent filings accelerating ahead of earnings upgrades before most of the sell-side had caught on. A former fixed-income quantitative analyst, he spent two decades building models that priced risk across emerging markets before pivoting to cover the economic impact of AI full-time. His writing translates opaque technical developments into clear risk/reward terms — and he's rarely diplomatic about the gap between AI valuations and underlying fundamentals. He believes most market participants still underestimate AI's long-run deflationary effect on knowledge work.
More from The Analyst →This Week's Edition
11 November 2026
14 articles
Related Articles
Related Articles
More Stories
© 2026 Cedar & Bloom. All rights reserved.